Viewing StudyNCT02978716



Ignite Creation Date: 2024-05-06 @ 9:24 AM
Last Modification Date: 2024-10-26 @ 12:14 PM
Study NCT ID: NCT02978716
Status: TERMINATED
Last Update Posted: 2022-03-23
First Post: 2016-11-18

Brief Title: Trilaciclib G1T28 a CDK 46 Inhibitor in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer mTNBC
Sponsor: G1 Therapeutics Inc
Organization: G1 Therapeutics Inc

Conditions & Keywords Data

Conditions:
Name
Triple-Negative Breast Cancer
Triple-Negative Breast Neoplasms
Breast Neoplasm
Breast Cancer
Keywords:
Name View
Metastatic View
Breast Cancer View
CDK 46 Inhibitor View
Triple Negative Breast Cancer View